RS 86 in the treatment of alzheimer's disease: Cognitive and biological effects

Eric Hollander, Michael Davidson, Richard C. Mohs, Thomas B. Horvath, Bonnie M. Davis, Zvi Zemishlany, Kenneth L. Davis

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Twelve patients who met Research Diagnostic Criteria for Alzheimer's disease (AD) completed a double-blind crossover study comparing oral RS 86, a long-acting and specific muscarinic agonist, with placebo. Cognitive and noncognitive effects were assessed with the Alzheimer's Disease Assessment Scale (ADAS). RS 86 was found to improve ADAS test scores consistently (both cognitive and noncognitive subscales) in seven patients, with a clinically obvious improvement in only two patients. RS 86 produced a significant increase in peak nocturnal cortisol levels, and this increase correlated with improvement on ADAS testing. Similarly, there was a 38% increase in amplitude of the P300 evoked potential with RS 86. The biological findings suggest that RS 86 was effective only to the extent that it enhanced central cholinergic activity.

Original languageEnglish (US)
Pages (from-to)1067-1078
Number of pages12
JournalBiological Psychiatry
Volume22
Issue number9
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Alzheimer Disease
Therapeutics
Muscarinic Agonists
Evoked Potentials
Double-Blind Method
Cross-Over Studies
Cholinergic Agents
Hydrocortisone
Placebos
2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione
Research

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Hollander, E., Davidson, M., Mohs, R. C., Horvath, T. B., Davis, B. M., Zemishlany, Z., & Davis, K. L. (1987). RS 86 in the treatment of alzheimer's disease: Cognitive and biological effects. Biological Psychiatry, 22(9), 1067-1078. https://doi.org/10.1016/0006-3223(87)90049-7

RS 86 in the treatment of alzheimer's disease : Cognitive and biological effects. / Hollander, Eric; Davidson, Michael; Mohs, Richard C.; Horvath, Thomas B.; Davis, Bonnie M.; Zemishlany, Zvi; Davis, Kenneth L.

In: Biological Psychiatry, Vol. 22, No. 9, 1987, p. 1067-1078.

Research output: Contribution to journalArticle

Hollander, E, Davidson, M, Mohs, RC, Horvath, TB, Davis, BM, Zemishlany, Z & Davis, KL 1987, 'RS 86 in the treatment of alzheimer's disease: Cognitive and biological effects', Biological Psychiatry, vol. 22, no. 9, pp. 1067-1078. https://doi.org/10.1016/0006-3223(87)90049-7
Hollander, Eric ; Davidson, Michael ; Mohs, Richard C. ; Horvath, Thomas B. ; Davis, Bonnie M. ; Zemishlany, Zvi ; Davis, Kenneth L. / RS 86 in the treatment of alzheimer's disease : Cognitive and biological effects. In: Biological Psychiatry. 1987 ; Vol. 22, No. 9. pp. 1067-1078.
@article{825c3267490c485baae0c364a647c4e0,
title = "RS 86 in the treatment of alzheimer's disease: Cognitive and biological effects",
abstract = "Twelve patients who met Research Diagnostic Criteria for Alzheimer's disease (AD) completed a double-blind crossover study comparing oral RS 86, a long-acting and specific muscarinic agonist, with placebo. Cognitive and noncognitive effects were assessed with the Alzheimer's Disease Assessment Scale (ADAS). RS 86 was found to improve ADAS test scores consistently (both cognitive and noncognitive subscales) in seven patients, with a clinically obvious improvement in only two patients. RS 86 produced a significant increase in peak nocturnal cortisol levels, and this increase correlated with improvement on ADAS testing. Similarly, there was a 38{\%} increase in amplitude of the P300 evoked potential with RS 86. The biological findings suggest that RS 86 was effective only to the extent that it enhanced central cholinergic activity.",
author = "Eric Hollander and Michael Davidson and Mohs, {Richard C.} and Horvath, {Thomas B.} and Davis, {Bonnie M.} and Zvi Zemishlany and Davis, {Kenneth L.}",
year = "1987",
doi = "10.1016/0006-3223(87)90049-7",
language = "English (US)",
volume = "22",
pages = "1067--1078",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - RS 86 in the treatment of alzheimer's disease

T2 - Cognitive and biological effects

AU - Hollander, Eric

AU - Davidson, Michael

AU - Mohs, Richard C.

AU - Horvath, Thomas B.

AU - Davis, Bonnie M.

AU - Zemishlany, Zvi

AU - Davis, Kenneth L.

PY - 1987

Y1 - 1987

N2 - Twelve patients who met Research Diagnostic Criteria for Alzheimer's disease (AD) completed a double-blind crossover study comparing oral RS 86, a long-acting and specific muscarinic agonist, with placebo. Cognitive and noncognitive effects were assessed with the Alzheimer's Disease Assessment Scale (ADAS). RS 86 was found to improve ADAS test scores consistently (both cognitive and noncognitive subscales) in seven patients, with a clinically obvious improvement in only two patients. RS 86 produced a significant increase in peak nocturnal cortisol levels, and this increase correlated with improvement on ADAS testing. Similarly, there was a 38% increase in amplitude of the P300 evoked potential with RS 86. The biological findings suggest that RS 86 was effective only to the extent that it enhanced central cholinergic activity.

AB - Twelve patients who met Research Diagnostic Criteria for Alzheimer's disease (AD) completed a double-blind crossover study comparing oral RS 86, a long-acting and specific muscarinic agonist, with placebo. Cognitive and noncognitive effects were assessed with the Alzheimer's Disease Assessment Scale (ADAS). RS 86 was found to improve ADAS test scores consistently (both cognitive and noncognitive subscales) in seven patients, with a clinically obvious improvement in only two patients. RS 86 produced a significant increase in peak nocturnal cortisol levels, and this increase correlated with improvement on ADAS testing. Similarly, there was a 38% increase in amplitude of the P300 evoked potential with RS 86. The biological findings suggest that RS 86 was effective only to the extent that it enhanced central cholinergic activity.

UR - http://www.scopus.com/inward/record.url?scp=0023261008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023261008&partnerID=8YFLogxK

U2 - 10.1016/0006-3223(87)90049-7

DO - 10.1016/0006-3223(87)90049-7

M3 - Article

C2 - 3651528

AN - SCOPUS:0023261008

VL - 22

SP - 1067

EP - 1078

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 9

ER -